{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T17:49:51Z","timestamp":1788112191017,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32 HL110837"],"award-info":[{"award-number":["T32 HL110837"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.tcm.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T21:53:42Z","timestamp":1743026022000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions"],"prefix":"10.1016","author":[{"given":"Andrew A.","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Asif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2025.03.002_bib0001","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1136\/heartjnl-2016-309914","article-title":"Amyloid heart disease: genetics translated into disease-modifying therapy","volume":"103","author":"Sperry","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.tcm.2025.03.002_bib0002","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1001\/jamacardio.2021.3070","article-title":"Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"6","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.tcm.2025.03.002_bib0003","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2025.03.002_bib0004","first-page":"273","article-title":"Best practices for prognostic evaluation of a patient with transthyretin amyloid cardiomyopathy","volume":"1","author":"Feng","year":"2019","journal-title":"JACC: CardioOncology"},{"key":"10.1016\/j.tcm.2025.03.002_bib0005","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1016\/S0140-6736(15)01274-X","article-title":"Systemic amyloidosis","volume":"387","author":"Wechalekar","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/j.tcm.2025.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tcm.2025.03.002_bib0007","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tcm.2025.03.002_bib0008","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1016\/j.echo.2022.06.006","article-title":"Practical points for echocardiography in cardiac amyloidosis","volume":"35","author":"Cuddy","year":"2022","journal-title":"Journal of the American Society of Echocardiography"},{"key":"10.1016\/j.tcm.2025.03.002_bib0009","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on Cardiac amyloidosis: JACC State-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2025.03.002_bib0010","first-page":"550","article-title":"Genomic screening for pathogenic transthyretin variants finds evidence of underdiagnosed amyloid cardiomyopathy from health records","volume":"3","author":"Carry","year":"2021","journal-title":"JACC: CardioOncology"},{"key":"10.1016\/j.tcm.2025.03.002_bib0011","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jaccao.2024.05.001","article-title":"Race and socioeconomic status impact diagnosis and clinical outcomes in transthyretin cardiac amyloidosis","volume":"6","author":"Shankar","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.tcm.2025.03.002_bib0012","first-page":"1368","article-title":"How to image cardiac amyloidosis","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC: Cardiovascular Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0013","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","article-title":"Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis","volume":"98","author":"Phelan","year":"2012","journal-title":"Heart"},{"key":"10.1016\/j.tcm.2025.03.002_bib0014","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.echo.2020.03.012","article-title":"Reduced diagnostic accuracy of apical-sparing strain abnormality for cardiac amyloidosis in patients with chronic kidney disease","volume":"33","author":"Singh","year":"2020","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.tcm.2025.03.002_bib0015","article-title":"Regional variability in longitudinal strain across vendors in patients with cardiomyopathy due to increased left ventricular wall thickness","volume":"12","author":"Sperry","year":"2019","journal-title":"Circulation: Cardiovascular Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0016","article-title":"Optimal echocardiographic parameters to improve the diagnostic yield of Tc-99m-bone avid tracer cardiac scintigraphy for transthyretin cardiac amyloidosis","volume":"15","author":"Cuddy","year":"2022","journal-title":"Circulation: Cardiovascular Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0017","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0018","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in Cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"14","author":"Dorbala","year":"2021","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/ehf2.12511","article-title":"Diagnostic performance of imaging investigations in detecting and differentiating cardiac amyloidosis: a systematic review and meta-analysis","volume":"6","author":"Brownrigg","year":"2019","journal-title":"ESC Heart Failure"},{"key":"10.1016\/j.tcm.2025.03.002_bib0020","first-page":"157","article-title":"Native T1 mapping in transthyretin amyloidosis","volume":"7","author":"Fontana","year":"2014","journal-title":"JACC: Cardiovascular Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0021","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jcmg.2018.02.006","article-title":"Native T1 and extracellular volume in transthyretin amyloidosis","volume":"12","author":"Martinez-Naharro","year":"2019","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0022","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jacc.2017.05.053","article-title":"Magnetic resonance in transthyretin cardiac amyloidosis","volume":"70","author":"Martinez-Naharro","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2025.03.002_bib0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jcmg.2023.10.010","article-title":"Current and evolving multimodality cardiac imaging in managing transthyretin amyloid cardiomyopathy","volume":"17","author":"Alwan","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0026","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jcmg.2013.09.019","article-title":"CMR imaging with rapid visual T1 assessment predicts mortality in patients suspected of cardiac amyloidosis","volume":"7","author":"White","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0027","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jcmg.2020.05.005","article-title":"Quantitative bone-avid tracer SPECT\/CT for cardiac amyloidosis: a crucial step forward","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102041","article-title":"American Society of Nuclear Cardiology quality metrics for cardiac amyloid radionuclide imaging","volume":"40","author":"Hage","year":"2024","journal-title":"Journal of Nuclear Cardiology"},{"key":"10.1016\/j.tcm.2025.03.002_bib0029","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 h and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.tcm.2025.03.002_bib0030","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis","volume":"28","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.tcm.2025.03.002_bib0031","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12350-022-02985-8","article-title":"Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM","volume":"30","author":"Sperry","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.tcm.2025.03.002_bib0032","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac 99mTc-pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.tcm.2025.03.002_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102019","article-title":"Quantitative 99mTc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy","volume":"39","author":"Vijayakumar","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.tcm.2025.03.002_bib0034","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"European Heart Journal - Cardiovascular Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0035","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/13506129.2023.2247136","article-title":"Reduction in 99mTc-DPD myocardial uptake with therapy of ATTR cardiomyopathy","volume":"31","author":"Rettl","year":"2024","journal-title":"Amyloid"},{"key":"10.1016\/j.tcm.2025.03.002_bib0036","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.122.014954","article-title":"Complete resolution of technetium pyrophosphate uptake after treatment of transthyretin cardiac amyloidosis","volume":"16","author":"Sperry","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0037","doi-asserted-by":"crossref","DOI":"10.1007\/s11886-024-02114-6","article-title":"Recent advances in positron emission tomography radiotracers to image cardiac amyloidosis","author":"Romero Pab\u00f3n","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.tcm.2025.03.002_bib0038","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1053\/j.semnuclmed.2024.05.012","article-title":"Radionuclide imaging of cardiac amyloidosis: an update and future aspects","volume":"54","author":"Clerc","year":"2024","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.tcm.2025.03.002_bib0039","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11886-021-01506-2","article-title":"Potential cardiac amyloid PET\/CT imaging targets for differentiating immunoglobulin light chain from transthyretin amyloidosis","volume":"23","author":"Schindler","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.tcm.2025.03.002_bib0040","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0041","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using 124I-Evuzamitide (124I-P5+14) versus 18F-florbetapir: a pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.tcm.2025.03.002_bib0042","unstructured":"I-124 Evuzamitide receives FDA's breakthrough designation for cardiac amyloidosis imaging. https:\/\/Www.AsncOrg\/n.d. https:\/\/www.asnc.org\/news\/i-124-evuzamitide-receives-fdas-breakthrough-designation-for-cardiac-amyloidosis-imaging\/ (accessed October 23, 2024)."},{"key":"10.1016\/j.tcm.2025.03.002_bib0043","article-title":"Preliminary evaluation of 99mTc-labeled peptide p5+14 for the detection of cardiopulmonary amyloidosis using SPECT\/CT and Planar Gamma scintigraphic imaging","volume":"65","author":"Wall","year":"2024","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.tcm.2025.03.002_bib0044","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1038\/s41467-021-22876-9","article-title":"A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy","volume":"12","author":"Huda","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.tcm.2025.03.002_bib0045","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.cardfail.2023.11.017","article-title":"EstimATTR: a simplified, machine-learning-based tool to predict the risk of wild-type transthyretin amyloid cardiomyopathy","volume":"30","author":"Casta\u00f1o","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.tcm.2025.03.002_bib0046","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1161\/CIRCULATIONAHA.118.034338","article-title":"Fully automated echocardiogram interpretation in clinical practice","volume":"138","author":"Zhang","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2025.03.002_bib0047","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2021.6059","article-title":"High-throughput precision phenotyping of left ventricular hypertrophy with cardiovascular deep learning","volume":"7","author":"Duffy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.tcm.2025.03.002_bib0048","article-title":"Impact of case and control selection on training artificial intelligence screening of cardiac amyloidosis","volume":"3","author":"Vrudhula","year":"2024","journal-title":"JACC: Advances"},{"key":"10.1016\/j.tcm.2025.03.002_bib0049","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/lt.24058","article-title":"Liver transplantation in transthyretin amyloidosis: issues and challenges","volume":"21","author":"Carvalho","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.tcm.2025.03.002_bib0050","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tcm.2025.03.002_bib0051","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","article-title":"Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial","volume":"79","author":"Coelho","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.tcm.2025.03.002_bib0052","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin Amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tcm.2025.03.002_bib0053","doi-asserted-by":"crossref","first-page":"16427","DOI":"10.1073\/pnas.202495199","article-title":"Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity","volume":"99","author":"Hammarstr\u00f6m","year":"2002","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.tcm.2025.03.002_bib0054","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.tcm.2025.03.002_bib0055","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.tcm.2025.03.002_bib0056","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.tcm.2025.03.002_bib0057","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","article-title":"The current state and future directions of RNAi-based therapeutics","volume":"18","author":"Setten","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tcm.2025.03.002_bib0058","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","article-title":"RNAi-based drug design: considerations and future directions","volume":"23","author":"Tang","year":"2024","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.tcm.2025.03.002_bib0059","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.tcm.2025.03.002_bib0060","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.tcm.2025.03.002_bib0061","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.tcm.2025.03.002_bib0062","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1001\/jama.2023.18688","article-title":"Eplontersen for hereditary transthyretin amyloidosis with polyneuropathy","volume":"330","author":"Coelho","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tcm.2025.03.002_bib0063","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.tcm.2025.03.002_bib0064","doi-asserted-by":"crossref","unstructured":"Fontana M., Berk J.L., Gillmore J.D., Witteles R.M., Grogan M., Drachman B., et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. New England Journal of Medicine n.d.;0. https:\/\/doi.org\/10.1056\/NEJMoa2409134.","DOI":"10.1056\/NEJMoa2409134"},{"key":"10.1016\/j.tcm.2025.03.002_bib0065","doi-asserted-by":"crossref","DOI":"10.1007\/s10741-024-10444-4","article-title":"Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis","author":"Girard","year":"2024","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.tcm.2025.03.002_bib0066","doi-asserted-by":"crossref","unstructured":"Fontana M., Solomon S.D., Kachadourian J., Walsh L., Rocha R., Lebwohl D., et al. CRISPR-Cas9 gene editing with Nexiguran Ziclumeran for ATTR cardiomyopathy. New England Journal of Medicine n.d.;0. https:\/\/doi.org\/10.1056\/NEJMoa2412309.","DOI":"10.1056\/NEJMoa2412309"},{"key":"10.1016\/j.tcm.2025.03.002_bib0067","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.tcm.2025.03.002_bib0068","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1056\/NEJMc2304584","article-title":"Antibody-associated reversal of ATTR amyloidosis\u2013Related cardiomyopathy","volume":"388","author":"Fontana","year":"2023","journal-title":"New England Journal of Medicine"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825000349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173825000349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T14:54:44Z","timestamp":1743778484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173825000349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":66,"alternative-id":["S1050173825000349"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2025.03.002","relation":{},"ISSN":["1050-1738"],"issn-type":[{"value":"1050-1738","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}